Problem

Miracle addresses the operational fragmentation that makes clinical trials slow, opaque, and labor-intensive for biotech teams. Trial data sits across EDC, IRT/RTSM, ePRO, central-lab, CTMS, recruitment, and safety systems, forcing teams to download, reconcile, and maintain spreadsheet trackers manually. That creates avoidable staff effort and errors, delays visibility into enrollment and safety issues, and consumes scarce resources at smaller biotechs. The killer use case is giving clinical-operations, medical, safety, and leadership teams a live view of enrollment, site performance, patient profiles, and safety events—especially important in rare-disease trials where every eligible participant matters.

Product / Service

Miracle is a healthcare SaaS platform positioned as a control room for clinical trials. It uses pre-built, vendor-agnostic connectors to ingest data from clinical-trial platforms and datasets into a secure, automated environment, replacing manual trackers with a unified dashboard. Users can move from high-level trial views to site- and patient-level details, while role-specific dashboards centralize communication across functions.

The platform also supports real-time safety monitoring and AI-assisted forecasting. Teams can monitor adverse events and patient data in context, project enrollment and trial-timeline scenarios from actual site performance, and model the effect of adding or removing sites. Miracle reports that customers such as Dianthus were operational in under a week, with the resulting benefit being less spreadsheet maintenance, faster issue detection, and more timely, data-driven decisions.

Market

Miracle competes in clinical-trial operations software, combining clinical-data integration, operational analytics, dashboarding, and forecasting within the broader healthcare enterprise-systems and HealthTech SaaS markets. Publicly identified alternatives include Oracle, MasterControl, and TriNetX, although Miracle’s emphasis is a vendor-agnostic operational layer across existing trial systems rather than simply a single trial-data repository. Its public materials show adoption by biopharma organizations, including case studies or partnerships involving Dianthus Therapeutics and Mineralys Therapeutics, alongside testimonials from other listed biopharma companies.

The company appears commercial rather than pre-revenue. PitchBook classifies Miracle as a private, venture-backed healthcare SaaS company, records a completed 2023 seed round, and labels it as generating revenue; it also reports $500,000 raised. GetLatka estimates $4.2 million of 2024 revenue and approximately 28 employees, but those private-company figures are estimates rather than audited disclosures. The combination of named customer deployments, public case studies, and reported revenue indicates early commercial traction, while the relatively small company and seed-stage financing suggest it remains an emerging competitor rather than an established incumbent.